Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Nov 27, 2023; 15(11): 2463-2469
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2463
Correlation between the expressions of metastasis-associated factor-1 in colon cancer and vacuolar ATP synthase
Miao He, Zuo-Feng Cao, Li Huang, Wen-Juan Zhong, Xue-Ming Xu, Xiao-Li Zeng, Jing Wang
Miao He, Li Huang, Wen-Juan Zhong, Xue-Ming Xu, Xiao-Li Zeng, Jing Wang, Department of Oncology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China
Zuo-Feng Cao, Department of Cardiology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China
Author contributions: He M, Cao ZF, Huang L, Zhong WJ, and Wu XM designed the research study; Zeng XL, Wang J, He M and Cao ZF performed the research; Cao ZF, Huang L, Zhong WJ and Xu XM analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Affiliated Hospital of Gannan Medical College, No. 20141219.
Informed consent statement: Informed consent is waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zuo-Feng Cao, MA, Attending Doctor, Department of Cardiology, The First Affiliated Hospital of Gannan Medical College, No. 128 Jinling West Road, Ganzhou Economic and Technological Development Zone, Ganzhou 341000, Jiangxi Province, China. caozuofeng123456@163.com
Received: July 27, 2023
Peer-review started: July 27, 2023
First decision: August 10, 2023
Revised: August 18, 2023
Accepted: October 17, 2023
Article in press: October 17, 2023
Published online: November 27, 2023
Processing time: 123 Days and 6.8 Hours
ARTICLE HIGHLIGHTS
Research background

Clinical prognosis often worsens due to high recurrence rates following radical surgery for colon cancer. The examination of high-risk recurrence factors post-surgery provides critical insights for disease evaluation and treatment planning.

Research motivation

The factors influencing the recurrence of colon cancer after surgery remains unclear.

Research objectives

To explore the relationship between metastasis-associated factor-1 in colon cancer (MACC1) and vacuolar ATP synthase (V-ATPase) expression in colon cancer tissues, and recurrence rate in patients undergoing radical colon cancer surgery.

Research methods

We selected 104 patients treated with radical colon cancer surgery at our hospital from January 2018 to June 2021. Immunohistochemical staining was utilized to assess the expression levels of MACC1 and V-ATPase in these patients.

Research results

The positive rates of MACC1 and V-ATPase were significantly higher in patients with recurrence compared to those without. Logistic regression analysis revealed TNM stage, lymph node metastasis, MACC1 expression, and V-ATPase expression as risk factors for postoperative colon cancer recurrence.

Research conclusions

The upregulated expression of MACC1 and V-ATPase in colon cancer patients appears to correlate with clinicopathological features and post-radical surgery recurrence.

Research perspectives

This study can serve as a reference for clinical prediction of the postoperative recurrence in colon cancer patients.